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OBJECTIVES: Understand the relationship between pharma-
cotherapy compliance and health care charges among primary
open-angle glaucoma (POAG) patients. METHODS: A retro-
spective case-control study utilizing the PharMetrics claims data-
base (1997–2006). Cases were identiﬁed as glaucoma patients
who had a glaucoma surgery (trabeculoplasty or trabeculectomy,
the ﬁrst identiﬁed as index date); controls were glaucoma patients
who did not have surgery (matched 1 : 2 on age, gender, and Charl-
son comorbidity index; last glaucoma medication prescription
served as index date). Both cases and controls were required to
have at least 2 years of continuous enrollment prior to index date.
Medication coverage was deﬁned as the percent of days during
which a patient was in possession of glaucoma medication over
the 2 years of follow-up pre-index date. The 75th percentile of
coverage served as the compliance/non-compliance cutoff. Glau-
coma-related charges (identiﬁed as claims with ICD-9 code
365.11) were assessed over the 2 years of follow-up pre-index
date. Multivariate linear regression models assessed the associa-
tion between compliance and glaucoma-related charges, while
controlling for key covariates. RESULTS: Cases (N = 3194) and
matched controls (N = 6388) did not vary substantially in descrip-
tive analyses. The mean coverage was signiﬁcantly higher for con-
trols (0.47, SD = 0.28) than for cases (0.45, SD = 0.29; P < 0.01).
The 75th-percentile of overall coverage (for both cases and con-
trols) was 0.69; this was used as the cutoff for compliant/non-
compliant patient categorization. When adjusting for covariates
(such as surgery status, descriptives, comorbidities, length of
enrollment, and duration of glaucoma), patients who were com-
pliant had had approximately 16.4% ($37) less glaucoma-related
health care charges ($188 vs. $225; p < 0.0001) than patients
who were not compliant. CONCLUSION: POAG patient com-
pliance with glaucoma medications is relatively low, which is com-
parable to other chronic diseases. Patients who are compliant have




PERSISTENCE,AND ASSOCIATED HEALTH CARE COSTS IN
OLDER ADULTS WITH GLAUCOMA
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OBJECTIVES: Depressive symptoms may have an impact on
patients’ medication use behavior and utilization of health care
services. This study examined association between depressive
symptoms and medication-related persistence and predictors of
associated health care charges in older adults (aged 65 and
above) with open angle glaucoma. METHODS: This study uti-
lized a retrospective cohort of older adults with primary open
angle glaucoma who completed a health status assessment upon
enrollment in plan, had a claim for open angle glaucoma (ICD-
9 codes), used glaucoma medications, and were enrolled in a
Medicare HMO. Duration of the study was from January 2000
to December 2002. The baseline assessment surveyed patients on
their demographics, health care service utilization in the year
prior to enrollment, lifestyle, and quality of life. Demographic,
clinical, and utilization-related economic variables were retrieved
from the administrative claims database of the patients’ HMO.
Survival analysis techniques were used to measure time to dis-
continuation (Persistence rate). The short-form Center for Epi-
demiologic Studies Depression Scale was used to assess level of
depressive symptomatology on a scale of 0 to 60. Associations
were examined using mixed-model multiple and logistic re-
gression approach. Sensitivity analysis that considered log-
transformed and untransformed speciﬁcations of the cost 
variable tested model appropriateness. RESULTS: A total of 268
patients were included. After controlling for potential con-
founders and temporal effects, depressive symptomatology was
associated with decreased medication-related persistence (p <
0.005). Patients who lived alone and had cardiovascular disease
showed higher odds of experiencing depressive symptoms (p <
0.005). Male gender was associated with decreased persistence
in glaucoma medications (p < 0.05). Health care charges
increased with increase in number of comorbidities and pre-
scriptions (p < 0.005). CONCLUSION: Presence of depressive
symptoms in patients lead to poor medication use behavior. Risk
assessment done upon enrollment offers the advantage of
improving health outcomes and reduce health care utilization.
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OBJECTIVES: To assess the minimal clinically important differ-
ence (MCID) of the Ocular Surface Disease Index® (OSDI®)
using multiple computation methods. METHODS: The OSDI is
a 12-item patient-reported outcomes (PRO) questionnaire specif-
ically designed to quantify ocular disability due to dry eye
disease. The Overall OSDI score ranges from 0 to 100; with
scores categorized by ocular disease severity, i.e. normal (0–12),
mild (13–22), moderate (23–32) and severe (33–100). To esti-
mate the MCID for the OSDI, we used data from the RESTORE
Registry study, which collects clinical, efﬁcacy, PRO, including
the OSDI, and safety data from patients with dry eye disease. 
We applied three anchor-based approaches to a clinician’s 
global impression rating (CGI) and a subject global assessment
(SGA). In each analysis, we computed one-way ANOVA with
different subsets of patients responding with the smallest clini-
cal change (minimal improvement/worsening for the CGI and
improved/worse for the SGA). Patients were included in 
our analysis if they completed the OSDI at baseline and at a 
subsequent follow-up visit and completed the SGA or their 
clinician completed the CGI. RESULTS: Data from 160 patients
were available. 84% of patients were Caucasian, 85% female,
and mean age was 59.7 years. Both the CGI and the SGA 
were signiﬁcantly correlated with the OSDI change score (r =
−0.350, p < 0.0001 and r = −0.443, p < 0.0001). Most patients
reported an improvement in OSDI scores. The mean change 
in OSDI score was similar for both anchors: −10.6 (N = 154, 
SD = 17.8) and −10.6 (N = 144, SD = 18.1), for the CGI 
and SGA, respectively. The MCID ranged from −4.9 to −8.7 for
the CGI anchor and from −7.7 to −9.0 for the SGA anchor.
CONCLUSION: Although preliminary, these results will assist
clinicians and researchers when interpreting change in OSDI
scores. The ongoing data collection from RESTORE will allow
future analyses of larger sample sizes to ﬁnalize the MCID 
estimates.
